These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9155163)

  • 1. [Overcoming of multidrug resistance by a newly synthesized quinoline compound, MS-209].
    Naito M; Nakanishi O; Tsuruo T
    Nihon Rinsho; 1997 May; 55(5):1122-7. PubMed ID: 9155163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
    Naito M; Tsuruo T
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer.
    Suzuki T; Fukazawa N; San-nohe K; Sato W; Yano O; Tsuruo T
    J Med Chem; 1997 Jun; 40(13):2047-52. PubMed ID: 9207946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative.
    Ganguly A; Banerjee K; Chakraborty P; Das S; Sarkar A; Hazra A; Banerjee M; Maity A; Chatterjee M; Mondal NB; Choudhuri SK
    Biomed Pharmacother; 2011 Sep; 65(6):387-94. PubMed ID: 21715129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209.
    Takeshita H; Kusuzaki K; Tsuji Y; Hirata M; Hashiguchi S; Nakamura S; Murata H; Ashihara T; Hirasawa Y
    Anticancer Res; 1998; 18(2A):739-42. PubMed ID: 9615713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene.
    Narasaki F; Oka M; Fukuda M; Nakano R; Ikeda K; Takatani H; Terashi K; Soda H; Yano O; Nakamura T; Doyle LA; Tsuruo T; Kohno S
    Cancer Chemother Pharmacol; 1997; 40(5):425-32. PubMed ID: 9272120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer.
    Duan Z; Li X; Huang H; Yuan W; Zheng SL; Liu X; Zhang Z; Choy E; Harmon D; Mankin H; Hornicek F
    J Med Chem; 2012 Apr; 55(7):3113-21. PubMed ID: 22400811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
    Naito M; Matsuba Y; Sato S; Hirata H; Tsuruo T
    Clin Cancer Res; 2002 Feb; 8(2):582-8. PubMed ID: 11839680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
    Nakanishi O; Baba M; Saito A; Yamashita T; Sato W; Abe H; Fukazawa N; Suzuki T; Sato S; Naito M; Tsuruo T
    Oncol Res; 1997; 9(2):61-9. PubMed ID: 9167187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance in chemotherapy for breast cancer.
    Saeki T; Tsuruo T; Sato W; Nishikawsa K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
    Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
    J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D; Dekel Y; Melikhov D; Margalit R
    Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
    Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
    Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance.
    Fu L; Liang Y; Deng L; Ding Y; Chen L; Ye Y; Yang X; Pan Q
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):349-56. PubMed ID: 14666379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.
    Coley HM
    Methods Mol Biol; 2010; 596():341-58. PubMed ID: 19949931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X; Sui M; Fan W
    Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
    Dietel M; Boss H; Reymann A; Pest S; Seidel A
    J Exp Ther Oncol; 1996 Jan; 1(1):23-9. PubMed ID: 9414385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.